Specialty pharmaceutical company PLx Pharma (NASDAQ:PLXP) had a day to remember on Tuesday, rising 27%. After market close on Monday, it revealed it had struck a deal with one of the top retailers on planet Earth.
PLx Pharma’s counterparty in the deal is Walmart (NYSE:WMT). The pharmaceutical company announced that its top product, the liquid aspirin capsule Vazalore, will be stocked in more than 4,500 Walmart stores throughout the U.S.
The company won’t have to wait long to start reaping the benefits of its Walmart presence; it said that three Vazalore offerings would start appearing on the retailer’s shelves next month. The stores will stock 81-milligram capsules in 12- and 30-count containers, and shoppers can opt for a 325 milligram version in a 30-count package.
“With Walmart’s broad reach and millions of customers, patients will have easy access to Vazalore in most of their stores nationwide,” PLx Pharma CEO Natasha Giordano said in a statement. “Walmart’s commitment is a real tribute to their recognition of Vazalore as an innovative aspirin therapy.”
PLx Pharma is making quick and big strides with Vazalore. The product — which is classified as a “drug delivery platform” because it neatly and safely transports liquid aspirin through the stomach to treat gastrointestinal difficulties — received FDA approval for supplemental New Drug Applications (sNDAs) for the above-mentioned dosages in March.
A deal with such a major retailer this early in the game bodes very well for Vazalore’s future. And, by extension, that of its maker.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Need Your Help Today. Your $1 can change life.